Edition:
India

STADA Arzneimittel AG (STAGn.DE)

STAGn.DE on Xetra

81.30EUR
17 Aug 2018
Change (% chg)

€0.20 (+0.25%)
Prev Close
€81.10
Open
€81.28
Day's High
€81.66
Day's Low
€80.86
Volume
25,167
Avg. Vol
43,071
52-wk High
€90.24
52-wk Low
€65.03

Select another date:

Thu, May 3 2018

BRIEF-STADA Says On Track To Meet Targets After Q1 Results

* DGAP-NEWS: STADA ARZNEIMITTEL AG: STADA WITH SOLID BUSINESS DEVELOPMENT IN THE FIRST QUARTER OF 2018

BRIEF-STADA Says Miguel Pagan To Become Head of Production

* SAYS MIGUEL PAGAN TO BECOME EXECUTIVE BOARD MEMBER FOR PRODUCTION AND DEVELOPMENT

BRIEF-Board Of STADA To File Application Related To Change Of Sub-Segment Of Stock Exchange

* DGAP-ADHOC: STADA ARZNEIMITTEL AG: EXECUTIVE BOARD OF STADA ARZNEIMITTEL AG DECIDES TO FILE APPLICATION RELATED TO CHANGE OF SUB-SEGMENT OF THE STOCK EXCHANGE

BRIEF-STADA Arzneimittel: Domination And Profit And Loss Transfer Agreement Takes Effect

* DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT BETWEEN STADA ARZNEIMITTEL AG AND NIDDA HEALTHCARE GMBH TAKES EFFECT / BEGINNING OF ACCEPTANCE PERIOD FOR SEVERANCE OFFER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-STADA Says Domination And Profit And Loss Transfer Agreement With Nidda Healthcare GmbH Takes Effect

* STADA SAYS DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT BETWEEN STADA ARZNEIMITTEL AG AND NIDDA HEALTHCARE GMBH TAKES EFFECT

Stada cuts dividend to focus on investments

BERLIN, March 8 German pharamceuticals company Stada is cutting its dividend to instead use the money for investments to grow its business and improve its position in the market.

BRIEF-Stada FY Net Income Down By 1 Pct At EUR 85.3 Mln

* GROUP SALES INCREASED IN 2017 FINANCIAL YEAR BY 8% TO EUR2,313.9M

BRIEF-STADA to propose a dividend of 0.11 euros per share

* DGAP-ADHOC: STADA: EXECUTIVE BOARD AND SUPERVISORY BOARD OF STADA ARZNEIMITTEL AG RESOLVE ON A PROPOSAL FOR THE APPROPRIATION OF PROFITS AND PROPOSE A DIVIDEND IN THE AMOUNT OF EUR0.11 PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Stada Says EMA Starts Evaluation Of Resubmitted Pegfilgrastim Application

* DGAP-NEWS: STADA ARZNEIMITTEL AG: EMA STARTED THE EVALUATION OF RESUBMITTED MARKETING AUTHORISATION APPLICATION FOR BIOSIMILAR PEGFILGRASTIM

Select another date: